SENESCO REPORTS RESULTS OF PRE-CLINICAL CANCER STUDY

Senesco Technologies reported the results of a mouse cancer study conducted at Ontario's University of Waterloo in which Factor 5A technology was used to treat mice with a type of melanoma that has an affinity for lung tissue which results in metastatic lung tumors.

After three weeks of treatment, the lungs of the treated and untreated mice were compared by weight to assess tumor load. The mice that received the Factor 5A treatment showed an average of 41 percent reduction in tumor weight relative to the untreated mice. Additionally, nearly half of the treated mice had lung weights that were statistically comparable to healthy mice that did not have any tumors. It has been previously shown that Factor 5A induces mouse lung tumors to undergo apoptosis.

The cancer cell line used to induce metastasis in this study is highly aggressive, and while it targets the lungs, it also causes tumor development in other organs. This rapid metastasis did not allow the course of treatment to run long enough to determine effect on longevity.